Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625
BackgroundProgressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostication in T1 non-progressors. We aimed to determine...
Main Authors: | Jerrold L. Boxerman, Bradley S. Snyder, Daniel P. Barboriak, Kathleen M. Schmainda |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1061502/full |
Similar Items
-
Practical guidance to identify and troubleshoot suboptimal DSC-MRI results
by: Melissa A. Prah, et al.
Published: (2024-02-01) -
Effect of Applying Leakage Correction on rCBV Measurement Derived From DSC-MRI in Enhancing and Nonenhancing Glioma
by: Fatemeh Arzanforoosh, et al.
Published: (2021-03-01) -
Dataset of voxelwise correlated signal values of ADC, rCBV and FAP-specific PET of 13 Glioblastoma patients
by: Manuel Röhrich, et al.
Published: (2020-08-01) -
CT Perfusion Derived rCBV < 42% Lesion Volume Is Independently Associated with Followup FLAIR Infarct Volume in Anterior Circulation Large Vessel Occlusion
by: Dhairya A. Lakhani, et al.
Published: (2024-04-01) -
Identification of single-dose, dual-echo based CBV threshold for fractional tumor burden mapping in recurrent glioblastoma
by: Aliya Anil, et al.
Published: (2023-01-01)